| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_220502f4465d0df4f6e058e25e45d626 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-69 |
| filingDate |
2010-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80a22531d8a943be24be23117c9cd5b1 |
| publicationDate |
2011-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011008372-A1 |
| titleOfInvention |
Enhancement of light activated drug therapy through combination with other therapeutic agents |
| abstract |
The efficacy of light activated therapy treatment is enhanced by use of additional therapeutic agents. Abnormal tissue is destroyed by light activated therapy, and the associated administration of one or more additional therapeutic agents can synergistically enhance the therapy. For example, the concepts disclosed herein encompass the use of the following agents in combination with light activated drug therapy: (1) agents that selectively inhibit heat shock protein 90 (Hsp90); (2) agents that inhibit the Hedgehog pathway (which is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, and which is implicated in many of the most deadly cancers); and, (3) agents for reducing the anti-apoptotic effects of Bcl-2 or Bcl-xL. These agents can be used with light activated drug therapy individually, or in various combinations and permutations. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012048891-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10376711-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011236402-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11529153-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8226946-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008033519-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458220-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010274330-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10307610-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11612669-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11425905-B2 |
| priorityDate |
2009-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |